These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31889326)

  • 21. Safety and Efficacy of Dupilumab in an Atopic Adolescent With Primary Immune Deficiency.
    Tanner JF; Knutsen AP; Siegfried E
    Dermatitis; 2021 Oct; 32(1S):e91-e92. PubMed ID: 34677168
    [No Abstract]   [Full Text] [Related]  

  • 22. Dupilumab for treatment of severe atopic dermatitis in a heart transplant recipient.
    Hamid RN; Bomar L; Strowd L
    Cutis; 2019 Jun; 103(6):E1-E2. PubMed ID: 31348459
    [No Abstract]   [Full Text] [Related]  

  • 23. Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab.
    Mollanazar NK; Savage KT; Pousti BT; Jariwala N; Del Guzzo C; Haun P; Vittorio C; Rook AH; Kim EJ
    Cutis; 2020 Sep; 106(3):131-132. PubMed ID: 33104116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ocular symptoms associated with dupilumab in atopic dermatitis].
    Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis.
    Cheng J; Jiang L; Morrow NC; Avdic A; Fairley JA; Ling JJ; Greiner MA
    J Am Acad Dermatol; 2021 Jul; 85(1):265-267. PubMed ID: 32956738
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and efficacy of dupilumab in a patient with severe atopic dermatitis and HIV infection, with 15 months of follow-up.
    Romagnuolo M; Angileri L; Tavecchio S; Marzano AV; Ferrucci S
    Clin Exp Dermatol; 2020 Aug; 45(6):762-763. PubMed ID: 32379943
    [No Abstract]   [Full Text] [Related]  

  • 27. Severe atopic dermatitis in a patient with Loeys-Dietz syndrome treated with dupilumab.
    Gkalpakiotis S; Maresova T
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e70-e72. PubMed ID: 35964299
    [No Abstract]   [Full Text] [Related]  

  • 28. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review.
    Raffi J; Suresh R; Botto N; Murase JE
    J Am Acad Dermatol; 2020 Jan; 82(1):132-138. PubMed ID: 31562940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report.
    Uchida H; Kamata M; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    Acta Derm Venereol; 2019 Jun; 99(7):675-676. PubMed ID: 30938821
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia.
    Fujishima C; Munemoto S; Hioki C; Sasaki H; Yoshida H; Yamamoto T; Kudo H
    Eur J Dermatol; 2022 May; 32(3):416-417. PubMed ID: 36065552
    [No Abstract]   [Full Text] [Related]  

  • 31. Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD.
    Ying Y; Shuang C; Zhen-Ying Z
    Immun Inflamm Dis; 2022 Mar; 10(3):e574. PubMed ID: 34953055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab therapy in a patient with atopic dermatitis and severe atopic keratoconjunctivitis.
    Gkalpakiotis S; Arenberger P; Skalicka P; Arenbergerova M
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):e281-e283. PubMed ID: 32031716
    [No Abstract]   [Full Text] [Related]  

  • 33. Diagnosis of Mycosis Fungoides Following Administration of Dupilumab for Misdiagnosed Atopic Dermatitis.
    Chiba T; Nagai T; Osada SI; Manabe M
    Acta Derm Venereol; 2019 Jul; 99(9):818-819. PubMed ID: 31045233
    [No Abstract]   [Full Text] [Related]  

  • 34. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term dupilumab therapy in Netherton syndrome with severe atopic manifestations: Case report and review of the literature.
    Özkaya E; Günay MB; Babuna Kobaner G; Keskinkaya Z; Gökalp MO
    Australas J Dermatol; 2023 May; 64(2):272-277. PubMed ID: 36745433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T
    Trichot C; Faucheux L; Karpf L; Grandclaudon M; Pattarini L; Bagot M; Mahévas T; Jachiet M; Saussine A; Bouaziz JD; Soumelis V
    J Allergy Clin Immunol; 2021 Feb; 147(2):756-759. PubMed ID: 32526313
    [No Abstract]   [Full Text] [Related]  

  • 37. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis.
    Yamane MLM; Belsito DV; Glass LRD
    Orbit; 2019 Oct; 38(5):390-394. PubMed ID: 30628518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restoration of sweating disturbance in atopic dermatitis treated with dupilumab.
    Mizukawa Y; Sato Y; Ohyama M; Shiohara T
    J Dermatol Sci; 2020 Oct; 100(1):79-81. PubMed ID: 32900571
    [No Abstract]   [Full Text] [Related]  

  • 39. Blocking type 2 inflammation by dupilumab does not control classic (type 1-driven) allergic contact dermatitis in chronic hand eczema.
    Crepy MN; Nosbaum A; Bensefa-Colas L
    Contact Dermatitis; 2019 Aug; 81(2):145-147. PubMed ID: 30851059
    [No Abstract]   [Full Text] [Related]  

  • 40. Dupilumab in a child with severe atopic dermatitis and severe asthma-a rare case with severe limbitis and exercise-induced anaphylaxis.
    Poelhekken M; Rosenberg FM; Oldhoff JM; Romeijn GLE; Wijdh RHJ; Bocca-Tjeertes IFA; Schuttelaar MLA
    Int J Dermatol; 2022 Oct; 61(10):e400-e401. PubMed ID: 35567488
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.